GeneHealth - Your precision medicine

Autosomal Recessive Polycystic Kidney Disease

Disease Details

Family Health Simplified

Buy Membership

Description: Autosomal recessive polycystic kidney disease (ARPKD) is a genetic disorder characterized by the development of fluid-filled cysts in the kidneys and liver, often leading to kidney failure and liver dysfunction.
Type: Autosomal recessive polycystic kidney disease (ARPKD) is inherited in an autosomal recessive manner. This means that an individual must inherit two copies of the faulty gene, one from each parent, to develop the disease. If both parents are carriers, each child has a 25% chance of having ARPKD.
Signs And Symptoms: Autosomal recessive polycystic kidney disease (ARPKD) is a genetic disorder affecting the kidneys. Signs and symptoms include:

1. Enlarged kidneys
2. High blood pressure (hypertension)
3. Frequent urinary tract infections
4. Liver abnormalities such as hepatic fibrosis
5. Respiratory difficulties in newborns due to enlarged kidneys compressing the lungs
6. Reduced kidney function, potentially leading to kidney failure

Newborns with ARPKD may have distended abdomens due to the enlarged kidneys, and older children may present with growth failure or poor weight gain.
Prognosis: For autosomal recessive polycystic kidney disease (ARPKD), the prognosis varies widely depending on the severity of the condition. In severe cases, particularly those detected prenatally or in infancy, it can lead to significant complications and may be life-threatening. Kidney and liver complications are common, with many patients eventually developing chronic kidney disease and requiring dialysis or a kidney transplant. Early detection, careful management, and treatment can improve outcomes and quality of life.
Onset: Autosomal recessive polycystic kidney disease (ARPKD) typically has an onset during infancy or early childhood. In some cases, symptoms can present even before birth, with enlarged kidneys detectable via prenatal ultrasound.
Prevalence: The prevalence of autosomal recessive polycystic kidney disease (ARPKD) is estimated to be between 1 in 20,000 to 1 in 40,000 live births.
Epidemiology: Autosomal Recessive Polycystic Kidney Disease (ARPKD) is a rare genetic disorder characterized by the development of cysts in the kidneys and sometimes in the liver. It typically presents in infancy or early childhood. The estimated incidence of ARPKD is approximately 1 in 20,000 live births. The disease is caused by mutations in the PKHD1 gene on chromosome 6, which encodes fibrocystin/polyductin, a protein thought to be involved in ductal morphogenesis of the kidney and liver.
Intractability: Autosomal recessive polycystic kidney disease (ARPKD) is generally considered a serious and challenging condition to manage, but it is not entirely intractable. There is currently no cure for ARPKD, and treatment primarily focuses on managing symptoms and complications. This may include blood pressure control, managing kidney function, addressing liver abnormalities, and potentially kidney or liver transplantation in severe cases. Early diagnosis and comprehensive medical care can improve the quality of life and outcomes for individuals with ARPKD.
Disease Severity: Autosomal recessive polycystic kidney disease (ARPKD) is generally severe. It often presents early in life, sometimes even prenatally, and can lead to serious complications including kidney failure and liver problems. The severity can vary, but the disease is typically life-threatening and requires comprehensive medical management.
Healthcare Professionals: Disease Ontology ID - DOID:0110861
Pathophysiology: Autosomal recessive polycystic kidney disease (ARPKD) is a genetic disorder characterized by the development of numerous fluid-filled cysts in the kidneys and liver. The pathophysiology involves mutations in the **PKHD1** gene, which encodes fibrocystin (also known as polyductin). Fibrocystin is expressed in the renal tubules and bile ducts.

Here’s a summarized breakdown of the pathophysiology:

1. **Genetic Mutation**: Mutations in the PKHD1 gene lead to defective or absent fibrocystin.
2. **Cyst Formation**: The lack of functional fibrocystin disrupts normal kidney and liver development and function, leading to the formation of cysts in the collecting ducts of the kidneys and biliary ducts of the liver.
3. **Disrupted Tubular Function**: The cysts interfere with normal kidney tubule function, impacting urine concentration and leading to potential kidney failure.
4. **Liver Complications**: The bile duct cysts can cause fibrosis and lead to congenital hepatic fibrosis, affecting liver function.

Patients often present with enlarged kidneys, hypertension, and varying degrees of renal impairment. The severity and progression can vary significantly among individuals.
Carrier Status: Autosomal recessive polycystic kidney disease (ARPKD) is caused by mutations in both copies of the PKHD1 gene. Individuals with only one mutated copy of the gene are considered carriers. Carriers do not typically display symptoms of the disease but can pass the mutated gene to their offspring. If two carriers have a child, there is a 25% chance that the child will inherit both mutated copies and develop ARPKD, a 50% chance that the child will inherit one mutated copy and be a carrier, and a 25% chance that the child will inherit two normal copies and be neither affected nor a carrier.
Mechanism: Autosomal recessive polycystic kidney disease (ARPKD) is a severe genetic disorder characterized by the development of numerous fluid-filled cysts in the kidneys and liver.

**Mechanism:**
ARPKD is caused by mutations in the PKHD1 gene, which encodes the protein fibrocystin (also known as polyductin). This protein is essential for normal kidney and liver development and function. In ARPKD, both copies of the PKHD1 gene must be mutated for the disease to manifest, following an autosomal recessive inheritance pattern.

**Molecular Mechanisms:**
1. **PKHD1 Gene Mutations:** The primary molecular mechanism involves mutations in the PKHD1 gene. These mutations lead to deficient or defective fibrocystin, affecting cell signaling pathways essential for the normal organization of kidney and liver tubules.

2. **Fibrocystin Dysfunction:** Normally, fibrocystin is involved in maintaining the structure and function of renal and biliary ducts. Loss or malfunction of fibrocystin due to PKHD1 mutations impairs cell-cell and cell-matrix interactions, leading to abnormal cell proliferation and cyst formation.

3. **Ciliary Dysfunction:** Fibrocystin is localized to the primary cilia of renal and biliary epithelial cells. Cilia are critical for cellular signaling and fluid balance. Dysfunctional fibrocystin disrupts these ciliary functions, contributing to abnormal cell growth and cystogenesis.

4. **Disrupted Signaling Pathways:** The lack of functional fibrocystin disrupts several signaling pathways, including those involving calcium signaling, cyclic AMP (cAMP) production, and planar cell polarity. These disruptions alter cell proliferation and fluid secretion, further promoting cyst development.

Overall, ARPKD results from complex interactions between defective fibrocystin and key intracellular signaling pathways, leading to abnormal kidney and liver structure and function.
Treatment: Currently, there is no cure for autosomal recessive polycystic kidney disease (ARPKD), but treatment focuses on managing symptoms and complications. This may include:

1. **Blood Pressure Control**: Medications such as ACE inhibitors or ARBs to manage high blood pressure.
2. **Infections**: Antibiotics for urinary tract infections or kidney infections.
3. **Kidney Function Monitoring**: Regular check-ups to monitor kidney function and progression of the disease.
4. **Dialysis or Transplant**: In advanced cases, dialysis or kidney transplantation may be required.
5. **Liver Issues**: Management of potential liver complications like hepatic fibrosis.
6. **Growth and Nutrition**: Nutritional support and growth monitoring in affected children.

Multidisciplinary care teams, including nephrologists, hepatologists, and pediatricians, often coordinate treatment plans.
Compassionate Use Treatment: Autosomal recessive polycystic kidney disease (ARPKD) is a genetic disorder characterized by the development of cysts in the kidneys and the liver. Regarding compassionate use treatments, off-label, or experimental treatments, here are some points to consider:

1. **Compassionate Use Treatments**: Compassionate use, also known as expanded access, allows patients with serious or life-threatening conditions to gain access to investigational medical products outside clinical trials when no comparable or satisfactory alternative therapy options are available. Specific treatments might vary, and a healthcare provider must apply for compassionate use on behalf of the patient.

2. **Off-label Treatments**: Doctors sometimes use drugs off-label to manage symptoms or complications associated with ARPKD. For example, medication like tolvaptan, primarily approved for autosomal dominant polycystic kidney disease, may occasionally be considered off-label. However, this should only be done under close medical supervision due to the lack of specific studies on ARPKD.

3. **Experimental Treatments**: Ongoing research includes gene therapy and other novel approaches like targeting specific pathways involved in cyst formation. Participation in clinical trials may provide access to some of these experimental therapies.

Always consult with a healthcare professional to explore the most current and suitable options.
Lifestyle Recommendations: For autosomal recessive polycystic kidney disease (ARPKD), lifestyle recommendations typically focus on managing symptoms and supporting overall health. Here are a few key areas to consider:

1. **Diet**: Adopt a balanced diet that's low in sodium to help manage blood pressure. Limit protein intake as per healthcare provider's advice to reduce kidney workload.

2. **Hydration**: Stay well-hydrated to support kidney function, but follow specific fluid restrictions if prescribed by a healthcare provider.

3. **Blood Pressure Management**: Regular monitoring and maintenance of blood pressure through diet, exercise, and medication if necessary.

4. **Regular Exercise**: Engage in moderate physical activity to maintain overall health and manage weight, which is important for blood pressure control and reducing cardiovascular risks.

5. **Avoid Nephrotoxic Substances**: Limit or avoid medications and substances that can harm the kidneys, such as nonsteroidal anti-inflammatory drugs (NSAIDs), and always consult with a healthcare provider before starting new medications.

6. **Regular Check-Ups**: Frequent medical check-ups to monitor kidney function, blood pressure, and overall health status.

7. **Emotional Support**: Consider counseling or support groups for emotional and mental well-being, as chronic illness can be stressful.

Always consult a healthcare provider for personalized advice tailored to individual health needs and circumstances.
Medication: For autosomal recessive polycystic kidney disease (ARPKD), there are currently no specific medications that can cure the disease. Treatment typically focuses on managing symptoms and complications, such as high blood pressure, infections, and kidney failure. This may involve:

1. Antihypertensive medications to control high blood pressure.
2. Diuretics to help reduce fluid buildup.
3. Antibiotics for urinary tract infections.
4. Medications or interventions to manage liver complications, since ARPKD can affect the liver.

In severe cases, dialysis or kidney transplantation may be necessary. Consult a healthcare provider for personalized treatment options.
Repurposable Drugs: As of now, there are no specific repurposable drugs approved for the treatment of autosomal recessive polycystic kidney disease (ARPKD). Treatment typically focuses on managing symptoms and complications, such as hypertension and kidney infections. Current research efforts are exploring potential therapies, but they have not yet identified a definitive repurposable drug for ARPKD.
Metabolites: For autosomal recessive polycystic kidney disease (ARPKD), the primary metabolites typically impacted are those involved in kidney function and bile acid metabolism, given that this disease affects both the kidneys and liver. Metabolites such as creatinine and urea may be elevated due to impaired kidney function. Additionally, because liver fibrosis and biliary dysgenesis are characteristic of ARPKD, bile acids and related metabolites may be disrupted. It's important to note that specific metabolomic profiles can vary, and metabolomic studies are often used to further understand the biochemical changes in ARPKD.
Nutraceuticals: Currently, there is no established evidence that nutraceuticals provide significant benefits for managing autosomal recessive polycystic kidney disease (ARPKD). Treatment typically focuses on managing symptoms, such as hypertension and kidney dysfunction. Always consult a healthcare provider for appropriate care options.
Peptides: Autosomal recessive polycystic kidney disease (ARPKD) is a genetic disorder characterized by the development of fluid-filled cysts in the kidneys and liver. Information about the specific involvement of peptides in ARPKD is limited, but research may focus on understanding protein interactions and pathways affected by mutations in the PKHD1 gene, which is responsible for the disease. Exploring peptide-based therapies or markers could potentially contribute to future treatment or diagnostic approaches.